GSK-3 beta inhibitors (CrystalGenomics/Yuyu)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameGSK-3 beta inhibitors (CrystalGenomics/Yuyu)
Drug Alias NameGSK-3 beta inhibitors (CrystalGenomics)GSK-3 inhbitors (CrystalGenomics)glycogen synthase kinase-3 beta inhibitors (Yuyu/CrystalGenomics)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 alpha inhibitorsGlycogen synthase kinase-3 beta inhibitors
TargetsGlycogen synthase kinase-3 alphaGlycogen synthase kinase-3 beta
Therapy Area/IndicationsDiabetes MellitusAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCrystalgenomics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesYuyu IncCrystalgenomics Inc
Active IndicationsN/A
Inactive IndicationsDiabetes MellitusAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A